Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial
Issued Date
2024-12-01
Resource Type
eISSN
20452322
Scopus ID
2-s2.0-85209228735
Journal Title
Scientific Reports
Volume
14
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Scientific Reports Vol.14 No.1 (2024)
Suggested Citation
Luk-In S., Leepiyasakulchai C., Saelee C., Keeratichamroen A., Srisangwan N., Ponprachanuvut P., Chammari K., Chatsuwan T., Wannigama D.L., Shein A.M.S., Kueakulpattana N., Srisakul S., Sranacharoenpong K. Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial. Scientific Reports Vol.14 No.1 (2024). doi:10.1038/s41598-024-79465-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102125
Title
Impact of resistant starch type 3 on fecal microbiota and stool frequency in Thai adults with chronic constipation randomized clinical trial
Corresponding Author(s)
Other Contributor(s)
Abstract
Constipation poses a significant health concern affecting individuals of varying ages and geographic locations worldwide. While the impacts of numerous probiotics on constipation are well-characterized, there has been limited assessment of the potential prebiotic effects of resistant starches. We therefore conducted a randomized, double-blind and placebo-controlled, clinical trial of resistant starch type 3 (RS-3) in Thai adults with self-reported chronic constipation. The effects of these mixed natural starch fibers on beneficial gut bacteria, bowel movements and stool consistency were evaluated after 6- and 12-week periods. Regardless of subject age, consumption of RS-3 compared to placebo resulted in significant improvements in gut health by dramatically increasing levels of beneficial bacteria (Bifidobacterium, Prevotella, Akkermansia and Megamonas) in the gut and relieving constipation. RS-3 consumption was associated with a significantly increased frequency of bowel movements, with subjects reporting these as healthy stools. Our findings provide important insights into the therapeutic advantages of RS-3 for constipation, and propose RS-3 as a feasible alternative strategy for management of constipation.